Phathom Pharmaceuticals, Inc. — Form 8-K Summary
Business Context and Reporting Period
Phathom Pharmaceuticals filed this Current Report on Form 8-K on September 27, 2021 under Item 8.01, Other Events. The filing reports results from VONO-103, a Phase 1, open-label, randomized crossover study evaluating vonoprazan 20 mg once daily versus lansoprazole 30 mg once daily in healthy U.S. subjects.
Key Operating and Financial Information
- Vonoprazan produced significantly greater acid inhibition than lansoprazole on Days 1 and 7.
- Mean 24-hour gastric pH on Day 1 was 4.6 for vonoprazan versus 2.8 for lansoprazole; the difference was statistically significant at p<0.0001.
- Mean 24-hour gastric pH on Day 7 was 5.9 for vonoprazan versus 3.8 for lansoprazole; the difference was statistically significant at p<0.0001.
- On Day 1, pH>4 holding-time ratio was 62.2% for vonoprazan versus 23.2% for lansoprazole.
- On Day 7, pH>4 holding-time ratio was 86.8% for vonoprazan versus 42.1% for lansoprazole.
- The least-squares mean difference in pH>4 holding-time ratio was 39.0 percentage points on Day 1 and 44.6 percentage points on Day 7, both with p<0.0001.
- Treatments were generally well tolerated, and no serious adverse events were reported.
- The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other balance-sheet metrics.
Material Changes, Outlook, and Risks
VONO-103 is described as the first pharmacokinetic, pharmacodynamic, and safety study directly comparing vonoprazan 20 mg once daily with lansoprazole 30 mg once daily. Phathom was also conducting the Phase 3 PHALCON-EE study in patients with erosive esophagitis, evaluating healing and maintenance of healing of erosions and relief of heartburn. Topline PHALCON-EE results were expected in October 2021.
The expected timing of PHALCON-EE topline results is forward-looking and could change. Reported topline data may be based on preliminary analyses and may change following audit and verification. Other identified risks include delays in NDA submissions, differing FDA feedback, reliance on third parties for manufacturing and clinical testing, regulatory developments, unexpected adverse effects or inadequate efficacy, uncertainty regarding QIDP and Fast Track designations, intellectual-property protection, compliance with the Takeda license agreement, and COVID-19-related disruption to clinical trials, manufacturing, supply chain, and operations.
Important Facts for Investors to Verify
- Verify the final audited PHALCON-EE results and whether they support regulatory submissions.
- Confirm whether vonoprazan’s efficacy and safety findings are replicated in the Phase 3 patient population.
- Review subsequent FDA interactions, NDA submission timing, and regulatory decisions.
- Assess the potential impact of adverse events, manufacturing dependencies, supply-chain disruption, and license or intellectual-property requirements.
- Consult the company’s periodic SEC filings for financial condition, liquidity, financing needs, and updated risk factors, which are not provided in this 8-K.